Search results
Novartis Ag (NVS) Q4 2022 Earnings Call Transcript
Motley Fool· 1 year agoImage source: The Motley Fool. Novartis Ag (NYSE: NVS) Q4 2022 Earnings Call Feb 01, 2023, 8:00 a.m. ET Contents: Prepared Remarks Questions and Answers...
Novartis AG's (VTX:NOVN) Stock Is Going Strong: Have Financials A Role To Play?
Simply Wall St. via Yahoo Finance· 4 months agoMost readers would already be aware that Novartis' (VTX:NOVN) stock increased significantly by 5.3%...
Most Shareholders Will Probably Agree With Novartis AG's (VTX:NOVN) CEO Compensation
Simply Wall St. via Yahoo Finance· 1 year agoKey Insights Novartis' Annual General Meeting to take place on 7th of March Salary of US$1.93m is...
Novartis AG (VTX:NOVN) is a favorite amongst institutional investors who own 51%
Simply Wall St. via Yahoo Finance· 8 months agoKey Insights Institutions' substantial holdings in Novartis implies that they have significant...
Novartis AG (VTX:NOVN) First-Quarter Results: Here's What Analysts Are Forecasting For This Year
Simply Wall St. via Yahoo Finance· 1 year agoInvestors in Novartis AG (VTX:NOVN) had a good week, as its shares rose 3.6% to close at CHF91.35...
Novartis AG (VTX:NOVN) most popular amongst individual investors who own 54% of the shares,...
Simply Wall St. via Yahoo Finance· 2 months agoKey Insights Novartis' significant individual investors ownership suggests that the key decisions...
Novartis (NVS) Q2 Earnings & Revenues Top, Guidance Raised
Zacks via Yahoo Finance· 10 months agoSwiss pharma giant Novartis AG NVS reported strong second-quarter 2023 results and shares are...
Why Novartis (NVS) Might Surprise This Earnings Season
Zacks via Yahoo Finance· 10 months agoInvestors are always looking for stocks that are poised to beat at earnings season and Novartis AG...
Novartis' Sandoz Foresees Rapid Growth Post Spin-Off in Generics Market Amid Upcoming Patent...
Benzinga via Yahoo Finance· 11 months agoNovartis AG's (NYSE: NVS) generics unit Sandoz tells investors it can add $3 billion in annual sales...
Exclusive-Novartis in the lead to acquire cancer drug developer MorphoSys-sources
Reuters via Yahoo News· 3 months ago(Reuters) -Drug maker Novartis AG is in advanced talks to acquire MorphoSys AG, a developer of...